(Continuation news of ORIONPHARM): The Company has reported Consolidated EPS of Tk. 4.01, Consolidated NAV per share (Including Revaluation Surplus) of Tk. 79.76, Consolidated NAV per share (Excluding Revaluation Surplus) of Tk. 71.79 and Consolidated NOCFPS of Tk. 11.07 for the year ended on June 30, 2021 as against Tk. 2.84, Tk. 76.77, Tk. 68.69 and Tk. 8.04 respectively for the same period of the previous year. (end)